As per market analysis, the Global Gastroprotective Molecules Market was valued at USD 9,684 Million in 2025 and is projected to reach USD 12,498 Million by 2033, growing at a CAGR of 4.60% from 2026 to 2033.
The market is witnessing steady growth driven by the increasing prevalence of gastrointestinal disorders, rising incidence of gastroesophageal reflux disease (GERD) and peptic ulcers, growing use of non-steroidal anti-inflammatory drugs (NSAIDs), and increasing awareness regarding the prevention and treatment of gastric acid-related conditions.
Increasing demand for effective acid-suppressing therapies, growing adoption of proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs), rising healthcare expenditure, and advancements in gastroprotective drug formulations are encouraging pharmaceutical companies to invest in new molecule development, combination therapies, improved drug-delivery systems, and broader distribution networks.